MAP2K6 and hepatocellular carcinoma: Based on the down-regulation of MAP2K6 in sh-APEX1-treated HCC cells and a positive expression correlation between APEX1 and MAP2K6 in HCC tissues (Figure 6A), we predicted that APEX1 enhances the malignant properties of HCC via its impact on MAP2K6 expression.